Health analytics

Why have we launched US access solutions?

Earlier this summer, we launched LCP Health Analytics’ US access solutions team to bring an integrated approach to US and ex US access and value consulting. US access solutions is co-led by Kevin Patterson and Lee Ann Steadman.

With decades of US commercialization and market access experience between them, the team works across four core services: pricing and reimbursement, payer value & communication, patient services and trade and channel.

Along with Jasim Uddin, Global Market Access Lead, US access solutions is part of an integrated global offering that brings together US and HTA market knowledge at a time that market access is more interconnected and complicated than ever.

For example, the Most Favoured Nation Executive Order marks a significant deviation from free market pricing for pharmaceutical products in the US.

In short, US pricing and access strategies are now more intertwined with ex-US, global access, and pricing strategies than ever before. The growing reliance of non-US reimbursement authorities that utilize health technology assessment (HTA) to systematically evaluate value underscores the increasing importance of robust real-world evidence, health outcomes, and economic data in shaping pricing and value communication strategies in US.

At a time of increasing fiscal constraints and an increasing informal role of the Institute for Clinical and Economic Research (ICER), health economics is emerging with increased utility in the US landscape more than in prior decades. Combining our US access expertise with HTA-level health economics expertise and collaboration with HTA bodies will bring novel insights to our US-based clients, particularly when it comes to their pricing and access strategies.

Core to LCP Health Analytics’ mission is to help shift healthcare systems from importers of illness to exporters of health and we have three particular cross-cutting areas of deep expertise.

Addressing health equity

We work with clients to address health equity from developing clinical trial plans to be more reflective of the populations that will benefit most from innovative medicines to embedding quantitative approaches that assess value at a societal and health equity levels by public and private payers.

Plan sponsors are calling for accountability on how insurance plans and third-party administrators are provisioning care, and quantitative approaches will continue to be requested to understand how specific therapies offer incremental value over current therapeutic options.

Broader value of medicines & health

Ae develop novel approaches to articulate and quantify the ‘broader value’ of medicines. This includes estimating the productivity impact or fiscal value (potential reduction in welfare benefits) yielded through the impact of new medicines alongside caregiver burden and other petals of the ISPOR Value Flower. With increasing impacts of multiple long term conditions on employee productivity and absenteeism, we will apply these novel approaches to the perspectives of US-specific payers and stakeholders. With over 60% of US employer-sponsored plans structured as self-insured and administered by insurance companies, delivering appropriate clinical interventions is just one component of the value expected. Both public and private sponsors increasingly prioritise outcomes like reduced absenteeism and improved productivity driven by healthier employees

Advanced technology and AI solutions

Our advanced technology and artificial intelligence solutions including interactive data visualizations like Medicines Nexus which provides prescription sales data, market opportunities and policy landscape for UK access and sales teams.

Our Transpose AI technology which provides accessible podcasts and videos tailored for different audiences which already provides more effective communication to medical communications, sales forces and internal training; this will provide impactful tools for value messaging for US payers.

Unique blend of team skills & experiences

A key strength of our team lies in the diversity of our skills and experiences. We bring together clinicians, former industry and government professionals, and decades of value-based consulting expertise - complemented by a strong foundation in advanced analytics. This blend enables us to collaborate effectively and tackle complex, multi-dimensional challenges with both rigour and insight. Our practical experience spans the full spectrum of client needs, from clinical trial planning and validating key assumptions for pricing and reimbursement strategies, to shaping competitive positioning and engagement strategies.

In the face of dynamic transformation occurring in the US market, driven by evolving macro- and micro-level policy landscapes, the rapid introduction of innovation, and increasing access to information for patients, providers, and payers, we see a pivotal opportunity. By partnering with organizations across the healthcare ecosystem, we aim to support the transition of the US healthcare system from an importer of illness to an exporter of health. This shift will be achieved through the realignment of value among stakeholders, ensuring that innovation, access, and outcomes are meaningfully connected.